Aronex Nyotran
Executive Summary
NDA filing for injectable nystatin anticipated in 1999, the company said in announcing the receipt of $5.6 mil. in milestone payments from Abbott Laboratories. The two payments are associated with the completion of patient enrollment and treatment required under the protocol for the Phase III study of Nyotran vs. amphotericin B in patients with presumed fungal infections in the U.S. and Europe. Aronex received a $2.8 mil. milestone payment in November